Adrenocortical carcinoma is a rare tumor of the adrenal cortex which accounts for no more than 0.2% of all malignancies, with two peaks of incidence in early childhood and adults over age 60. It represents an aggressive disease with up to two thirds of cases having distant metastases at the time of diagnosis and a mean survival of less than 30 months, 1-3 although combined treatment modalities, with special reference to mitotane-based therapy, seems to improve its outcome. 4 The differential diagnosis of carcinomas from adenomas has been based on several microscopic features, none of them being alone absolutely indicative of malignancy. 5, 6 Despite the majority of adrenocortical carcinomas do not represent a diagnostic pitfall in the clinical practice, there are several other cases in which the distinction from their benign counterparts is not straightforward.
These cases are a challenge for the pathologist, since the therapeutic strategy in adrenocortical carcinomas is radically different from that of adenomas and an accurate diagnosis is mandatory.
This issue is also relevant because adrenal tumors are increasingly recognized in clinical practice:
the widespread use of imaging techniques has resulted in the clinical dilemma of the adrenal incidentaloma, 7 and although the vast majority of adrenal incidentalomas are benign lesions, in up to 12% of cases an incidental adrenocortical carcinoma may be discovered. 8 Different scoring systems for adrenocortical carcinoma have therefore been developed, using mathematical models or numerical scores based on the association of a given threshold for each considered parameter to malignancy. [9] [10] [11] The most widely employed scoring system was proposed 11 and revisited in a subsequent report 12 Recently, a different approach based on the definition of an algorithm centred on mitotic count (>5/50HPF), followed by the recognition of other parameters (including nuclear grade, diffuse growth pattern and tissue reaction) was proposed, 17 and although based on a relatively small series of malignant cases -defined by the presence of metastases -it had the advantage of simplifying the current diagnostic approach based on numerical scores.
A second major issue is the distinction between morphologically and clinically malignant adrenocortical tumors. Not all adrenal tumors having unequivocal microscopic features of malignancy progress to fatal outcome, therefore a better definition of the clinical and pathological features that impact on prognosis and a stratification of adrenal cancer patients into prognostic categories are needed. Among the most commonly used pathological parameters for the diagnosis of adrenocortical carcinoma, mitotic activity and/or proliferative index showed a significant association with survival, 10,12,18 as age and overall Weiss score did, as well. 19 In a very large study on metastatic tumors aimed to recognize prognostic rather than diagnostic parameters, multivariate analysis identified the presence of a mitotic rate >20x50HPF and the number of organs involved as the major factors that influence prognosis in advanced adrenal cancer patients. 20 The aim of the present study was to reconsider the clinical pathological parameters currently used in the diagnosis of adrenocortical carcinoma in a large retrospective series of 92 cases diagnosed and treated at one Institution, with the aim to revise the classical diagnostic scoring systems in an algorithmic approach and to provide a pathologically-based prognostic stratification of adrenal cancer patients. Table 1 .
Histochemistry and immunohistochemistry.
In selected cases, to confirm the adrenocortical nature of the lesion, immunohistochemical 
Results
Distribution of the Weiss's parameters in adrenocortical tumors.
The summary of the Weiss's parameter(s) distribution in the whole series of 139 adrenocortical neoplasms is reported in Table 2 . None of the parameters reached both 100% sensitivity and specificity for the diagnosis of adrenocortical carcinoma. All but three parameters (presence of diffuse architecture, nuclear atypia and eosinophilic cytoplasm) were 100% specific for a diagnosis of adrenocortical carcinoma. The most sensitive feature was necrosis, that was recognizable in 84% of cases, followed by mitotic count exceeding 5 in 50 HPF (71%) and venous invasion (64%). The presence of atypical mitoses was highly specific but it was observed in 34% of cases, only. The algorithm takes into consideration the presence of a disrupted reticulin framework, that was the single most sensitive feature of malignancy, followed by at least one of the three parameters with 100% specificity and highest sensitivity and specificity, namely mitotic count >5x50HPF, 
Prognostic stratification of adrenocortical carcinoma patients.
A secondary aim of the present study was the prognostic stratification of adrenocortical cancer patients. Among the clinical and pathological parameters investigated by means of univariate analysis, advanced stage (stage 3 and 4; p=0.007), mitotic count higher than the median value of 9 (p=0.02), presence of atypical mitoses (p=0.047), Weiss score higher than 6 (p=0.02), and Weiss modified score higher than 5 (p=0.02) were significantly associated to a worse overall survival, whereas age over the median of 45 years (p=0.04), stage (stage 3 and 4; p=0.008) and mitotic count over the median value of 9 (p=0.04) were associated to a shorter disease free survival. Multivariate Cox regression model showed an independent prognostic role, at both disease free and overall survival analysis, for stage, mitotic count and presence of diffuse growth pattern ( Table   3 ).
Based on multivariate analysis, adrenocortical carcinomas were re-classified into three risk groups according to the status of the independent prognostic factors (diffuse growth pattern was excluded, being part of the diagnostic algorithm as the first step criterion for adrenal carcinoma).
Survival analysis demonstrated that the stratification of adrenocortical cancer patients according to the scheme proposed was strongly correlated to disease free (p<0.007) and overall (p<0.005) outcome status (Figure 3) . Our first observation stemmed by the re-evaluation of the concept of diffuse growth pattern, that in both Weiss' original papers 11, 12 and also in a recent study 17 was highlighted as a major diagnostic feature for adrenal cancer, although less relevant for others. 14 In summary, in the present paper an easy-to-perform and highly specific and sensitive algorithm for the diagnosis of malignant adrenocortical tumors was designed, and a clinically relevant prognostic categorization of adrenal cancer patients was additionally provided. 
